Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 62
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
JAMA ; 322(10): 946-956, 2019 09 10.
Artículo en Inglés | MEDLINE | ID: mdl-31503309

RESUMEN

Importance: Disability persists after hip fracture in older persons. Current rehabilitation may not be sufficient to restore ability to walk in the community. Objective: To compare a multicomponent home-based physical therapy intervention (training) with an active control on ability to walk in the community. Design, Setting, and Participants: Parallel, 2-group randomized clinical trial conducted at 3 US clinical centers (Arcadia University, University of Connecticut Health Center, and University of Maryland, Baltimore). Randomization began on September 16, 2013, and ended on June 20, 2017; follow-up ended on October 17, 2017. Patients aged 60 years and older were enrolled after nonpathologic, minimal trauma hip fracture, if they were living in the community and walking without human assistance before the fracture, were assessed within 26 weeks of hospitalization, and were not able to walk during daily activities at the time of enrollment. A total of 210 participants were randomized and reassessed 16 and 40 weeks later. Interventions: The training intervention (active treatment) (n = 105) included aerobic, strength, balance, and functional training. The active control group (n = 105) received transcutaneous electrical nerve stimulation and active range-of-motion exercises. Both groups received 2 to 3 home visits from a physical therapist weekly for 16 weeks; nutritional counseling; and daily vitamin D (2000 IU), calcium (600 mg), and multivitamins. Main Outcomes and Measures: The primary outcome (community ambulation) was defined as walking 300 m or more in 6 minutes at 16 weeks after randomization. The study was designed to test a 1-sided hypothesis of superiority of training compared with active control. Results: Among 210 randomized participants (mean age, 80.8 years; 161 women [76.7%]), 197 (93.8%) completed the trial (187 [89.0%] by completing the 6-minute walk test at 16 weeks and 10 [4.8%] by adjudication of the primary outcome). Among these, 22 of 96 training participants (22.9%) and 18 of 101 active control participants (17.8%) (difference, 5.1% [1-sided 97.5% CI, -∞ to 16.3%]; 1-sided P = .19) became community ambulators. Seventeen training participants (16.2%) and 15 control participants (14.3%) had 1 or more reportable adverse events during the intervention period. The most common reportable adverse events reported were falls (training: 6 [5.7%], control: 4 [3.8%]), femur/hip fracture (2 in each group), pneumonia (training: 2, control: 0), urinary tract infection (training: 2, control: 0), dehydration (training: 0, control: 2), and dyspnea (training: 0, control: 2). Conclusions and Relevance: Among older adults with a hip fracture, a multicomponent home-based physical therapy intervention compared with an active control that included transcutaneous electrical nerve stimulation and active range-of-motion exercises did not result in a statistically significant improvement in the ability to walk 300 m or more in 6 minutes after 16 weeks. Trial Registration: ClinicalTrials.gov Identifier: NCT01783704.


Asunto(s)
Fracturas de Cadera/rehabilitación , Modalidades de Fisioterapia , Anciano , Anciano de 80 o más Años , Terapia por Ejercicio/métodos , Femenino , Servicios de Atención de Salud a Domicilio , Humanos , Masculino , Rango del Movimiento Articular , Estimulación Eléctrica Transcutánea del Nervio , Prueba de Paso
2.
Clin Diabetes ; 35(3): 154-161, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28761217

RESUMEN

IN BRIEF Several contraindications limit the use of metformin, most notably the risk of lactic acidosis. This article reports on an examination of a population of patients with diabetes with preserved renal function to evaluate provider compliance with guidelines on metformin use and to identify factors that contributed when practice diverged from recommendations. It found that metformin was withheld from approximately one-third of these patients because of 1) an existent contraindication to metformin, 2) patient behavior or preference, or 3) provider preference or bias based on patient or personal factors. Although providers generally follow current recommendations for the use of metformin, deviations from guidelines in practice are common.

3.
Nutr Cancer ; 66(1): 68-76, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24274259

RESUMEN

Postmenopausal breast cancer survivors are living longer; however, a common class of drugs, aromatase inhibitors (AI), depletes estrogen levels, promotes bone loss, and heightens fracture risk. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may offset AI effects to bone because of the known effects on cellular processes of bone turnover. Therefore, we hypothesized that 4 g of EPA and DHA daily for 3 mo would decrease bone turnover in postmenopausal breast cancer survivors on AI therapy in a randomized, double-blind, placebo controlled pilot study that included 38 women. At baseline and 3 mo, serum fatty acids, bone turnover, and inflammatory markers were analyzed. Serum EPA and DHA, total and long-chain (LC) omega (n)-3 polyunsaturated fatty acids (PUFA) increased, whereas arachidonic acid, total and LC n-6 PUFA, and the LC n-6:n-3 PUFA ratio decreased compared to placebo (all P < .05). Bone resorption was inhibited in the fish oil responders compared to placebo (P < .05). Inflammatory markers were not altered. This short-term, high-dose fish oil supplementation study's findings demonstrate that fish oil can reduce bone resorption; however, longer-term studies are needed to assess bone density preservation and to explore mechanistic pathways in this population at high risk for bone loss.


Asunto(s)
Resorción Ósea/tratamiento farmacológico , Suplementos Dietéticos , Ácidos Docosahexaenoicos/administración & dosificación , Ácido Eicosapentaenoico/administración & dosificación , Anciano , Anciano de 80 o más Años , Inhibidores de la Aromatasa/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Ácidos Docosahexaenoicos/sangre , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Ácido Eicosapentaenoico/sangre , Ingestión de Energía , Ácidos Grasos/sangre , Femenino , Aceites de Pescado/administración & dosificación , Humanos , Persona de Mediana Edad , Proyectos Piloto , Posmenopausia , Sobrevivientes
4.
BMC Endocr Disord ; 14: 58, 2014 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-25022877

RESUMEN

BACKGROUND: α-amidation is a final, essential step in the biosynthesis of about half of all peptide hormones and neurotransmitters. Peptidylglycine α-amidating monooxygenase (PAM), with enzymatic domains that utilize Cu and Zn, is the only enzyme that catalyzes this reaction. PAM activity is detected in serum, but its significance and utility as a clinical biomarker remain unexplored. METHODS: We used well-established enzymatic assays specific for the peptidylglycine-α -hydroxylating monooxygenase (PHM) and peptidyl-α-hydroxyglycine α-amidating lyase (PAL) domains of PAM to quantify amidating activity in the sera of 144 elderly men. Relationships between PHM and PAL activity and serum levels of their respective active-site metals, Cu and Zn, were analyzed. Study participants were also genotyped for eight non-coding single nucleotide polymorphisms (SNPs) in PAM, and relationships between genotype and serum enzyme activity and metal levels were analyzed. RESULTS: Serum PHM and PAL activities were normally distributed and correlated linearly with each other. Serum PAL activity, but not serum PHM activity, correlated with serum Cu; neither activity correlated with serum Zn. Study subjects possessing the minor alleles for rs32680 had lower PHM and PAL activities, and subjects with minor alleles for rs11952361 and rs10515341 had lower PHM activities. CONCLUSIONS: Our results characterize large variation in serum amidating activity and provide unique insight into its potential origin and determinants. Common non-coding polymorphisms affect serum amidating activity and Cu levels. Serum amidating activity should be explored as a biomarker for functionality in the elderly and in additional study groups.


Asunto(s)
Cobre/sangre , Oxigenasas de Función Mixta/genética , Oxigenasas de Función Mixta/metabolismo , Complejos Multienzimáticos/genética , Complejos Multienzimáticos/metabolismo , Polimorfismo de Nucleótido Simple/genética , Zinc/sangre , Anciano , ADN/genética , Femenino , Genotipo , Humanos , Masculino , Espectrometría de Masas , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa
5.
Am J Addict ; 23(5): 459-65, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24628943

RESUMEN

BACKGROUND: Varenicline carries a black box warning for neuropsychiatric adverse events. OBJECTIVE: We examined varenicline use and past history of major depressive disorder (MDD) on depressive symptoms during smoking cessation. METHOD: This is a secondary analysis of two smoking cessation studies in 152 postmenopausal women who received placebo or nicotine patch, or 78 women who received varenicline with relaxation. Lifetime history of MDD (LH-MDD) was assessed at baseline and women with current MDD were excluded. Center for Epidemiologic Study Depression scale (CESD) measured depressive symptoms at baseline, 6 and 12 weeks. RESULTS: Baseline CESD scores were 5.3 + 4.4. Those with a LH-MDD reported higher CESD scores (p > .001). Those taking varenicline reported lower scores over all time periods compared to nicotine or placebo (p < .01). The differences between varenicline and the other treatments remained when controlling for LH-MDD, indicating an independent effect. CESD scores were associated with concurrent smoking status (p < .001), and with withdrawal symptoms (p < .001). CONCLUSION: CESD score were lower in those receiving varenicline, whether this is due to an anti-depressant effect, subject selection, use of relaxation or another cause is unknown. Varenicline does not increase depressive symptoms during smoking cessation in postmenopausal women without current MDD. Subjects with a LH-MDD are susceptible to developing depressive symptoms during smoking cessation, regardless of pharmacologic aid. SCIENTIFIC SIGNIFICANCE: Pharmacologic aids did not increase depression symptoms in this select population of postmenopausal women without current depression. Smoking cessation does increase depressive symptoms in those with LH-MDD, though the degree of increase was not clinically meaningful.


Asunto(s)
Benzazepinas/uso terapéutico , Depresión/inducido químicamente , Trastorno Depresivo Mayor/tratamiento farmacológico , Nicotina/uso terapéutico , Posmenopausia/psicología , Quinoxalinas/uso terapéutico , Cese del Hábito de Fumar/psicología , Fumar/tratamiento farmacológico , Fumar/psicología , Benzazepinas/efectos adversos , Terapia Combinada , Depresión/psicología , Trastorno Depresivo Mayor/terapia , Femenino , Humanos , Persona de Mediana Edad , Nicotina/efectos adversos , Agonistas Nicotínicos/uso terapéutico , Placebos , Quinoxalinas/efectos adversos , Terapia por Relajación , Fumar/terapia , Síndrome de Abstinencia a Sustancias/psicología , Dispositivos para Dejar de Fumar Tabaco/efectos adversos , Vareniclina
6.
Int J Vitam Nutr Res ; 84(3-4): 124-32, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-26098476

RESUMEN

Animal and human studies indicate that omega (n)-3 polyunsaturated fatty acids (PUFA) can influence bone health. We conducted a randomized, double-blind, placebo-controlled trial of the effects of n-3 long chain (LC) PUFA supplementation (N-3 LCPUFA) on red blood cell (RBC) fatty acid levels and bone turnover markers in older postmenopausal women. One hundred and twenty-six postmenopausal women (mean age 75±7 years) were treated with n-3 LCPUFA (1.2 g eicosapentaenoic acid [EPA]/docosahexaenoic acid [DHA]/day, n=85) or placebo (olive oil, n=41) for 6 months. All women received 315 mg calcium citrate and 1000 IU cholecalciferol. RBC DHA (weight %) increased in the n-3 LCPUFA group, compared to no change in the placebo group (P<0.001). The ratio of DHA+EPA:arachidonic acid (AA) increased by 42 % in the n-3 LCPUFA group and by 5% in the placebo group (P<0.001). Bone-specific alkaline phosphatase and osteocalcin decreased in the n-3 LCPUFA group (P<0.05) with no between-group difference. Short-term n-3 LCPUFA supplementation increased RBC concentrations of DHA and n-3:n-6 ratios. Bone turnover decreased with n-3 LCPUF, but not statistically compared to placebo. The results point to the need for investigations with greater dosages of n-3 LCPUFA for a longer duration to understand the contribution to bone metabolism in postmenopausal women.


Asunto(s)
Remodelación Ósea/efectos de los fármacos , Ácidos Grasos Omega-3/administración & dosificación , Anciano , Anciano de 80 o más Años , Suplementos Dietéticos , Ácidos Docosahexaenoicos/administración & dosificación , Ácidos Docosahexaenoicos/sangre , Método Doble Ciego , Ácido Eicosapentaenoico/administración & dosificación , Ácido Eicosapentaenoico/sangre , Eritrocitos/química , Ácidos Grasos/sangre , Ácidos Grasos Omega-3/sangre , Ácidos Grasos Omega-6/sangre , Femenino , Humanos , Placebos , Posmenopausia
7.
Curr Osteoporos Rep ; 11(3): 203-12, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23857286

RESUMEN

Age-related bone and muscle loss are major public health problems. Investigational therapies to reduce these losses include anti-inflammatory dietary supplementations, such as polyunsaturated fatty acids (PUFA). Surprisingly, this topic has received little attention in the osteoporosis community. Recent research highlights the role of PUFA in inflammatory regulation of bone remodeling via cellular pathways. Emerging research suggests significant roles for PUFA in reducing bone and muscle loss with aging; however, findings are conflicted for PUFA and fracture risk. Limited studies suggest a relation between higher omega-3 FA and better muscle/bone in older adults. This review highlights new research since 2008 and synthesizes our current understanding of PUFA in relation to bone and muscle. Across study designs, evidence indicates that PUFA has positive effects upon bone. As data are sparse, future clinical trials and prospective studies are important to determine the long term benefits of PUFA supplementation upon bone and muscle outcomes.


Asunto(s)
Huesos/efectos de los fármacos , Suplementos Dietéticos , Ácidos Grasos Insaturados/farmacología , Músculo Esquelético/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Envejecimiento/efectos de los fármacos , Envejecimiento/fisiología , Densidad Ósea/efectos de los fármacos , Densidad Ósea/fisiología , Resorción Ósea/epidemiología , Resorción Ósea/prevención & control , Huesos/fisiología , Ácidos Grasos Insaturados/uso terapéutico , Femenino , Fracturas Óseas/epidemiología , Fracturas Óseas/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Músculo Esquelético/fisiología , Factores de Riesgo
8.
Curr Opin Lipidol ; 22(1): 16-20, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21102327

RESUMEN

PURPOSE OF REVIEW: Both dietary calcium and vitamin D are undoubtedly beneficial to skeletal health. In contrast, despite intense investigation, the impact of dietary protein on calcium metabolism and bone balance remains controversial. A widely held view is that high intakes of animal protein result in increased bone resorption, reduced bone mineral density, and increased fractures because of its ability to generate a high fixed metabolic acid load. The purpose of this review is to present the recent or most important epidemiological and clinical trials in humans that evaluated dietary protein's impact on skeletal health. RECENT FINDINGS: Many epidemiological studies have found a significant positive relationship between protein intake and bone mass or density. Similarly, isotopic studies in humans have also demonstrated greater calcium retention and absorption by individuals consuming high-protein diets, particularly when the calcium content of the diet was limiting. High-protein intake may positively impact bone health by several mechanisms, including calcium absorption, stimulation of the secretion of insulin-like growth factor-1, and enhancement of lean body mass. The concept that an increase in dietary protein induces a large enough shift in systemic pH to increase osteoclastic bone resorption seems untenable. SUMMARY: Recent epidemiological, isotopic and meta-analysis studies suggest that dietary protein works synergistically with calcium to improve calcium retention and bone metabolism. The recommendation to intentionally restrict dietary protein to improve bone health is unwarranted, and potentially even dangerous to those individuals who consume inadequate protein.


Asunto(s)
Huesos/metabolismo , Calcio/metabolismo , Proteínas en la Dieta/metabolismo , Humanos
9.
J Orthop Sports Phys Ther ; 51(2): CPG1-CPG81, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33522384

RESUMEN

Hip fracture is a leading cause of profound morbidity in individuals aged 65 years and older, ranking in the top 10 causes of loss of disability-adjusted life-years for older adults. Worldwide, the number of people with hip fracture is expected to rise significantly due to the aging population and other factors. Physical therapist management is recommended within medical, surgical, and multidisciplinary clinical practice guideline (CPGs) and is considered to be the standard of care in rehabilitation for people with hip fracture. The goal of this CPG was to review the evidence relevant to physical therapist management and to provide evidence-based recommendations for physical therapy diagnosis, prognosis, intervention, and assessment of outcome in adults with hip fracture. J Orthop Sports Phys Ther 2021;51(2):CPG1-CPG81. doi:10.2519/jospt.2021.0301.


Asunto(s)
Fracturas de Cadera/terapia , Modalidades de Fisioterapia , Accidentes por Caídas/prevención & control , Anciano , Fracturas de Cadera/fisiopatología , Humanos , Evaluación de Resultado en la Atención de Salud , Manejo del Dolor , Dimensión del Dolor , Examen Físico
10.
Am Heart J ; 160(5): 893-9, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21095277

RESUMEN

BACKGROUND: Vitamin D is a fat-soluble hormone necessary for calcium homeostasis. Recently, studies have demonstrated that vitamin D may be important to the health of the cardiovascular system. METHODS: Adults ≥ 50 years of age with heart failure were recruited for assessment of serum 25-hydroxyvitamin D (25OHD) concentrations. Cardiopulmonary exercise testing was used to assess functional capacity. Proximal muscle strength was evaluated with a Biodex isokinetic dynamometer [corrected] (Biodex, Shirley, NY), and health status was assessed with the Kansas City Cardiomyopathy Questionnaire. Univariate associations between physical performance and health status measures and 25OHD followed by a linear regression model were used to study associations, adjusting for other potential explanatory variables. RESULTS: Forty adults 67.8 ± 10.9 years of age (55% women and 57.5% African American) with mean ejection fraction 40% were analyzed (New York Heart Association class II in 70% and class III in 30%). Comorbidities included 77.5% hypertension and 47.5% diabetes. The mean 25OHD concentration was 18.5 ± 9.1 ng/mL, and mean peak Vo2, 14 ± 4 mL/kg/min. In univariate regression analysis, 25OHD was positively associated with peak Vo2 (P = .045). Multivariable regression analysis sustained positive association between 25OHD and peak Vo2 (P = .044) after adjusting for age, race, and respiratory exchange ratio (adjusted R² = 0.32). Association between proximal muscle strength with the 25OHD concentration was not significant. The Kansas City Cardiomyopathy Questionnaire physical limitation domain score was negatively associated with 25OHD (P = .04) but was not sustained in multivariable analysis. CONCLUSIONS: 25-Hydroxyvitamin D may be an important marker or modulator of functional capacity in patients with heart failure. Randomized controlled trials are needed to assess the effect of vitamin D repletion on functional performance.


Asunto(s)
Tolerancia al Ejercicio/fisiología , Insuficiencia Cardíaca/sangre , Vitamina D/análogos & derivados , Vitamina D/administración & dosificación , Anciano , Biomarcadores/sangre , Método Doble Ciego , Prueba de Esfuerzo , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Fuerza Muscular/fisiología , Pronóstico , Índice de Severidad de la Enfermedad , Volumen Sistólico/fisiología , Encuestas y Cuestionarios , Vitamina D/sangre , Vitamina D/farmacocinética , Vitaminas/administración & dosificación , Vitaminas/farmacocinética
11.
J Biomed Opt ; 13(4): 044018, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19021346

RESUMEN

Determining the health of muscle cells by in vivo imaging could impact the diagnosis and monitoring of a large number of congenital and acquired muscular or cardiac disorders. However, currently used technologies are hampered by insufficient resolution, lack of specificity, or invasiveness. We have combined intrinsic optical second-harmonic generation from sarcomeric myosin with a novel mathematical treatment of striation pattern analysis, to obtain measures of muscle contractile integrity that correlate strongly with the neuromuscular health of mice suffering from genetic, acquired, and age-related decline in skeletal muscle function. Analysis of biopsies from a pilot group of human volunteers suggests a similar power in quantifying sarcopenic changes in muscle integrity. These results provide the first strong evidence that quantitative image analysis of sarcomere pattern can be correlated with physiological function, and they invite the application of SHG imaging in clinical practice, either in biopsy samples or via microendoscopy.


Asunto(s)
Algoritmos , Inteligencia Artificial , Interpretación de Imagen Asistida por Computador/métodos , Microscopía/métodos , Enfermedades Musculares/patología , Reconocimiento de Normas Patrones Automatizadas/métodos , Sarcómeros/patología , Animales , Humanos , Aumento de la Imagen/métodos , Ratones , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad
12.
Alzheimer Dis Assoc Disord ; 22(3): 255-60, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18580590

RESUMEN

BACKGROUND: Medical, functional, and behavioral problems are associated with transitions from assisted living (AL), but limited information is available on those at highest risk for transition. METHODS: We conducted a multidisciplinary geriatric team assessment of individuals newly admitted to 2 dementia-specific AL communities from January 2000 to March 2002. Transitions of individuals to permanent skilled nursing facilities (SNF) was assessed for 9 months. Multidisciplinary assessment on admission included medical and cognitive evaluations, physical function, nutritional status, and psychosocial adjustment. RESULTS: Twenty-four men and 24 women with a mean age of 83+/-6 years were assessed. Mental status score was 15+/-6. Residents had 2.1+/-1.7 comorbidities and were prescribed 1.7+/-1.2 medications. During follow-up, 23 (47.9%) transitioned to SNF and 9 (18.8%) individuals died (censored events). Significant predictors of transfer to nursing home from AL by one-predictor Cox proportional hazards model included depression score [hazard ratio (HR) 1.19; P=0.008], dependent activities of daily living (HR 1.18; P=0.014), gait speed (HR 1.15; P=0.004), modified Berg Balance Score (HR 0.88; P=0.004), and mental status score (HR 0.924, P=0.034). Our multivariate model selected by the forward procedure indicates that the modified Berg Balance Scale score predicted transfer to permanent nursing home with a interquartile HR of 0.91 (95% CI 0.8264, 0.989). CONCLUSIONS: A significant number of new residents of dementia-specific AL transitioned to SNF over 9 months. In univariate analysis, depression score, walking speed, balance, and mental status score were significantly associated with transition and in multivariate analysis, balance performance predicted transfer. These results suggest that fall risk should receive attention on admission to AL to potentially mitigate the high transfer rate.


Asunto(s)
Instituciones de Vida Asistida , Demencia/fisiopatología , Demencia/psicología , Transferencia de Pacientes , Instituciones de Cuidados Especializados de Enfermería , Accidentes por Caídas/prevención & control , Anciano de 80 o más Años , Femenino , Evaluación Geriátrica/métodos , Humanos , Masculino , Actividad Motora/fisiología , Pruebas Neuropsicológicas , Transferencia de Pacientes/estadística & datos numéricos , Equilibrio Postural/fisiología
13.
Eur J Appl Physiol ; 102(2): 223-31, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17943308

RESUMEN

Muscle power and strength decrease with age leading to reduced independence and increased health risk from falls. Creatine supplementation can increase muscle power and strength. The purpose of this study was to examine the effects of 7 days of creatine supplementation on body composition, muscular strength, and lower-body motor functional performance in older women. Thirty 58-71 year old women performed three test sessions (T1-T3) each separated by one week. Each session consisted of one repetition maximum tests for bench press and leg press, and isometric hand-grip, tandem gait, upper-body ergometer, and lower-body ergometer tests. Following T2, subjects were assigned to a creatine monohydrate (0.3 g kg body mass(-1) for 7 days) (CR: 63.31 +/- 1.22 year, 160.00 +/- 1.58 cm, 67.11 +/- 4.38 kg) or a placebo (PL: 62.98 +/- 1.11 year, 162.25 +/- 2.09 cm, 67.84 +/- 3.90 kg) supplementation group. CR significantly (P < 0.05) increased bench press (1.7 +/- 0.4 kg), leg press (5.2 +/- 1.8 kg), body mass (0.49 +/- 0.04 kg) and fat free mass (0.52 +/- 0.05) and decreased completion time on the functional tandem gait tests from T2-T3. No significant changes were found for PL on any of the measured variables. No adverse side-effects were reported by either group. Short-term creatine supplementation resulted in an increase in strength, power, and lower-body motor functional performance in older women without any adverse side effects.


Asunto(s)
Creatina/administración & dosificación , Suplementos Dietéticos , Contracción Muscular/fisiología , Músculo Esquelético/fisiología , Esfuerzo Físico/fisiología , Análisis y Desempeño de Tareas , Administración Oral , Factores de Edad , Femenino , Humanos , Persona de Mediana Edad , Contracción Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Esfuerzo Físico/efectos de los fármacos
14.
Am J Geriatr Cardiol ; 17(1): 7-12, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18174754

RESUMEN

Patients with heart failure (HF) are at increased risk for frailty, and identification is challenging. The authors assessed the distance on the 6-minute walk test (6MWT) as a measure of frailty in 60 older HF patients (ejection fraction

Asunto(s)
Anciano Frágil , Insuficiencia Cardíaca/fisiopatología , Anciano , Anciano de 80 o más Años , Progresión de la Enfermedad , Prueba de Esfuerzo , Tolerancia al Ejercicio , Femenino , Indicadores de Salud , Humanos , Masculino , Fenotipo , Factores de Riesgo , Volumen Sistólico , Factores de Tiempo
15.
J Am Geriatr Soc ; 55(3): 426-31, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17341247

RESUMEN

OBJECTIVES: To evaluate the effect of ultra-low-dose (0.25 mg/d) micronized 17beta-estradiol on cognitive function in older postmenopausal women. DESIGN: Randomized, placebo-controlled trial conducted for 3 years. SETTING: Academic health center in greater Hartford, Connecticut. PARTICIPANTS: Fifty-seven healthy, community-dwelling, older postmenopausal women. INTERVENTION: Women received 0.25 mg/d of micronized 17beta-estradiol (estrogen therapy (ET), n=32) or placebo (n=25); all women who had not had a hysterectomy received 100 mg/d of oral micronized progesterone for 2-week periods every 6 months. MEASUREMENTS: Neuropsychological measures of memory, language, mood, and executive function were collected at baseline, 3 months, and 36 months. Measures of executive function included the Controlled Oral Word Association Test, the Trail Making Test, and the Wisconsin Card Sorting Test. The Boston Naming Test was used to measure language skills. The Symbol Digit Modalities Test was used as a measure of sustained attention. Measures of memory included the Complex Figure Test, Fuld Object Memory Test, and a selected subtest from the Wechsler Memory Scale. Scores from the Geriatric Depression Scale and the Beck Anxiety Inventory were used to assess symptoms of depression. RESULTS: No differences were found between ET and placebo on any of the neurocognitive measures or depression instruments, nor were there any differences when the groups were stratified according to age. CONCLUSION: This small study, which had adequate power to detect change in some but not all domains of cognition tested, revealed that low-dose estrogen neither benefits nor harms cognitive function in older women after 3 years of treatment, but confirmation is needed from larger trials.


Asunto(s)
Climaterio/efectos de los fármacos , Cognición/efectos de los fármacos , Estradiol/administración & dosificación , Pruebas Neuropsicológicas , Afecto/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Densidad Ósea/efectos de los fármacos , Connecticut , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Cuidados a Largo Plazo , Persona de Mediana Edad
16.
Nutrients ; 9(5)2017 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-28492492

RESUMEN

Controversy exists as to whether high glycemic index/glycemic load (GI/GL) diets increase the risk of chronic inflammation, which has been postulated as a pathogenic intermediary between such diets and age-related alterations in body composition and insulin resistance. We conducted an ancillary study to a randomized, double-blind trial comparing the effects of a whey protein supplement (PRO, n = 38) and a maltodextrin supplement (CHO, n = 46) on bone density to evaluate the impact of a calibrated increase in GI/GL on inflammation, insulin resistance, and body composition in a healthy aging population. Markers of inflammation, HOMA, body composition, and GI/GL (estimated from 3-day food records) were assessed at baseline and 18 months. By 18 months, the GL in the CHO group increased by 34%, 88.4 ± 5.2 → 118.5 ± 4.9 and did not change in the PRO group, 86.5 ± 4.1 → 82.0 ± 3.6 (p < 0.0001). Despite this change there were no differences in serum CRP, IL-6, or HOMA at 18 months between the two groups, nor were there significant associations between GL and inflammatory markers. However, trunk lean mass (p = 0.0375) and total lean mass (p = 0.038) were higher in the PRO group compared to the CHO group at 18 months There were also significant associations for GL and change in total fat mass (r = 0.3, p = 0.01), change in BMI (r = 0.3, p = 0.005), and change in the lean-to-fat mass ratio (r = -0.3, p = 0.002). Our data suggest that as dietary GL increases within the moderate range, there is no detectable change in markers of inflammation or insulin resistance, despite which there is a negative effect on body composition.


Asunto(s)
Dieta , Proteínas en la Dieta/administración & dosificación , Índice Glucémico , Inflamación , Resistencia a la Insulina , Anciano , Biomarcadores , Composición Corporal , Femenino , Humanos , Polisacáridos/administración & dosificación , Posmenopausia , Estados Unidos , Proteína de Suero de Leche/administración & dosificación
17.
J Clin Densitom ; 9(3): 309-14, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16931349

RESUMEN

The goal of this study is to determine the associations between the components of a frailty definition and bone mineral density (BMD) in older men. A total of 392 community dwelling men (age range: 58-95 yr) with a mean age of 73+/-8 yr were evaluated. Femoral neck BMD T-scores ranged from -5.78 to +2.50, with 48.7% who had T-scores between -1 and -2.5 (low bone mass) and 8.7% who had T scores < or = -2.5 (osteoporosis). Participants were characterized as normal (39%), intermediate (55%), or frail (6%). Hand grip strength was 31.5+/-9.1 kg in those with normal BMD compared with 26.5+/-7.9 kg in those with osteoporotic BMD (p=0.0026). Walk speed (8 ft) was 2.32+/-0.49 s in those with normal BMD compared with 2.87+/-1.30 s with osteoporotic BMD (p=0.0015). Femoral neck T-score declined significantly with increasing level of frailty (p=0.014), but significance of decline was lost when corrected for age. Increasing frailty was associated with lower femoral neck BMD, although the association was not independent of age. Two components of the frailty model (i.e., hand grip strength and walking speed) were independently associated with lower femoral neck BMD, a finding that has not previously been reported in men.


Asunto(s)
Densidad Ósea/fisiología , Anciano Frágil , Absorciometría de Fotón , Anciano , Anciano de 80 o más Años , Cuello Femoral/diagnóstico por imagen , Cuello Femoral/metabolismo , Fuerza de la Mano/fisiología , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/diagnóstico por imagen , Osteoporosis/metabolismo , Osteoporosis/fisiopatología
18.
J Palliat Med ; 19(10): 1087-1091, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27623357

RESUMEN

BACKGROUND: There is often little information on long-term prognosis available for Emergency Medicine physicians when decisions on admission, treatment, or consultations are being made for patients. There is a new focus to understand if palliative support should be offered in the emergency department (ED) and the Palliative Performance Scale (PPS), a screening tool used in other settings in palliative care, has been little used in the ED. OBJECTIVE: The goal of this study was to assess the prognostic value of the PPS in predicting three- and six-month survival in patients admitted through the ED. DESIGN: A prospective cohort study. SETTING/SUBJECTS: We evaluated 123 patients over the age of 55 years admitted through the ED of a tertiary care hospital in New England in November and December of 2013. MEASUREMENTS: Each patient's PPS score was evaluated initially in the ED, with follow-up assessments of PPS and survival at three and six months. RESULTS: Baseline PPS for the 123 patients was 72 ± 22. Information on 72 subjects (58.5%) at three months was 60 assessed and 12 deaths. Information on 47 subjects (38.2%) at six months was 26 assessed and 21 deaths (nine further deaths from three months). There were no significant differences in the demographics or PPS score in those evaluated and those lost to follow-up at three or six months. Patients with an initial PPS score of 30 or less had 14% survival at six months. CONCLUSION: In this small preliminary study, The PPS score may predict survival in patients admitted to the hospital through the ED. The ease of use holds promise that use of the PPS in the ED may help ED physicians predict survival and plan for better disposition, advocate for patient wishes, and initiate palliative care consultation.

19.
J Acad Nutr Diet ; 116(11): 1767-1775, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27568885

RESUMEN

BACKGROUND: A Mediterranean-style diet (MedSD) is associated with positive health outcomes, particularly reduced risk of cardiovascular disease. It is of interest to assess the feasibility of adherence to a MedSD in a subset of older adults in the United States. OBJECTIVE: To assess the efficacy of implementing a MedSD intervention in a subset of postmenopausal women living in the United States, and to detect the influence of this dietary pattern on blood lipid levels. DESIGN: A partial feeding, nutrition counseling, pilot study with a one-group longitudinal design. PARTICIPANTS: Sixteen healthy, postmenopausal, American women living in suburban communities in Farmington, CT, with a mean±standard deviation age of 77±6.8 years and a body mass index of 26.1±3.1. INTERVENTION: Participants were counseled by a registered dietitian nutritionist on how to follow a MedSD, which included increased sources of n-3 polyunsaturated fatty acids, fruits, and vegetables, and decreased saturated fat, n-6 polyunsaturated fatty acids, and simple sugars for 12 weeks. To maintain isocaloric conditions, participants were asked to substitute sources of saturated fat and refined carbohydrates for extra virgin olive oil (3 T/day), walnuts (1.5 oz/day), and fatty fish (3 to 5 servings/wk), which were provided at 3-week intervals. MAIN OUTCOME MEASURES: Dietary adherence measures included the Mediterranean Diet Score, 3-day diet records, and serum fatty acid and lipid profiles. STATISTICAL ANALYSES: Mixed model longitudinal analyses were conducted to assess changes over time (Weeks 0, 12, and 24) in the outcome variables. RESULTS: Mediterranean Diet Score increased by 8.9 points (P<0.001) after the MedSD phase. Dietary sugar decreased by 10.8 g (P<0.05), total dietary n-3 increased by 1.6 g (P<0.01), total dietary n-6 increased by 5.5 g (P<0.01), and dietary n-6:n3 ratio decreased by 3.6 units (P<0.01). In serum, 22:6 (n-3), 20:5 (n-3), and 18:3 (n-3) increased (P<0.001, P<0.01, and P<0.001, respectively), and 14:0, 16:0, 17:0, 20:4 (n-6), 22:4 (n-6) declined after the intervention (P<0.01, P<0.001, P<0.01, P<0.01, and P<0.001, respectively), which support a change in dietary intake toward a MedSD. Serum high-density lipoprotein cholesterol levels increased by 3.8 mg/dL (0.098 mmol/L) (P<0.05) and serum triglyceride levels decreased by 11.6 mg/dL (0.131 mmol/L) (P<0.10). CONCLUSIONS: A pilot study of a 12-week MedSD intervention with counseling from a registered dietitian nutritionist can favorably influence the dietary pattern and lipid profile of postmenopausal women living in the United States.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Dieta Mediterránea/psicología , Cooperación del Paciente , Posmenopausia , Anciano , Enfermedades Cardiovasculares/prevención & control , Connecticut , Consejo/métodos , Ácidos Grasos/sangre , Femenino , Voluntarios Sanos , Humanos , Lípidos/sangre , Estudios Longitudinales , Proyectos Piloto , Factores de Riesgo , Factores de Tiempo
20.
J Am Geriatr Soc ; 64(1): 144-50, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26782864

RESUMEN

OBJECTIVES: To compare the relative predictive power of handgrip and leg extension strength in predicting slow walking. DESIGN: Report of correlative analysis from two epidemiological cohort studies. SETTING: Foundation of the National Institutes of Health Sarcopenia Project. PARTICIPANTS: Men and women aged 67 to 93 (N=6,766). MEASUREMENTS: Leg strength, handgrip strength, and gait speed were measured. Strength cutpoints associated with slow gait speed were developed using classification and regression tree analyses and compared using ordinary least squares regression models. RESULTS: The cutpoints of lower extremity strength associated with slow gait speed were 154.6 N-m in men and 89.9 N-m in women for isometric leg extension strength and 94.5 N-m in men and 62.3 N-m in women for isokinetic leg extension strength. Weakness defined according to handgrip strength (odds ratios (OR)=1.99 to 4.33, c-statistics=0.53 to 0.67) or leg strength (ORs=2.52 to 5.77; c-statistics=0.61 to 0.66) was strongly related to odds of slow gait speed. Lower extremity strength contributed 1% to 16% of the variance and handgrip strength contributed 3% to 17% of the variance in the prediction of gait speed depending on sex and mode of strength assessment. CONCLUSION: Muscle weakness of the leg extensors and forearm flexors is related to slow gait speed. Leg extension strength is only a slightly better predictor of slow gait speed. Thus, handgrip and leg extension strength appear to be suitable for screening for muscle weakness in older adults.


Asunto(s)
Envejecimiento/fisiología , Extremidades/fisiopatología , Marcha/fisiología , Fuerza de la Mano/fisiología , Debilidad Muscular/diagnóstico , Sarcopenia/diagnóstico , Caminata/fisiología , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Femenino , Humanos , Masculino , Fuerza Muscular , Debilidad Muscular/etiología , Debilidad Muscular/fisiopatología , Debilidad Muscular/prevención & control , Valor Predictivo de las Pruebas , Sarcopenia/etiología , Sarcopenia/fisiopatología , Sarcopenia/prevención & control , Factores Sexuales , Estadística como Asunto , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA